Ischemia is caused by sudden extreme restriction in blood supply that leads to metabolic stress, due to oxygen and glucose deprivation to a tissue. Hippocampus, which plays an important role in learning and memory, is known as one of the earliest brain regions to be damaged following ischemia with high vulnerability both in animals [1] [2] [3] [4] and in humans.
5)
Thus much research has been done to find potential therapeutics to ameliorate damages to the hippocampus caused by ischemic insult. In vitro hippocampal oxygen-glucose deprivation (OGD) has been widely used as an in vitro ischemia model 6, 7) to assess the neuroprotective properties of potential therapeutic drugs. Electrophysiological hallmarks of in vitro OGD in acute rat hippocampal neurons are neuronal dysfunctions such as cell death, excitability degeneration and decrease in excitatory synaptic transmissions. 8, 9) Therefore, a substance that can attenuate both neuronal death and electrophysiological degeneration induced by OGD can be considered as a potential neuroprotective agent that could have clinical implications in counteracting ischemia.
Sulbutiamine is a highly lipid soluble synthetic analogue of vitamin B1 (thiamine) and is already being used clinically to treat asthenia. 10) It can cross the blood brain barrier (BBB) more easily than thiamine thus it has significant advantage over thiamine in bioavailability by oral intake. 10) Especially, it has been shown that sulbutiamine can directly increase thiamine level in the hippocampus 10) and, in addition, in vitro experiments where neuroblastoma cells were incubated in 10 mM of sulbutiamine showed ten-fold increase in intracellular thiamine content. 11) Various studies indicate that thiamine deficiency alone can have harmful effects on neuronal viability in the hippocampus 12) and to further support the importance of thiamine in cell viability, there are reports suggesting the role of thiamine in enhancing the survival of cultured neurons 13) and attenuating cell death caused by ischemia in cardiomyocytes. 14) Interestingly, with its favorable properties of readily crossing the BBB and increasing thiamine availability in tissues, 10) sulbutiamine has recently been shown to have neuroprotective effect on retinal ganglion cells under trophic factor deprivation-induced apoptotic cell death 15) and it can improve energy metabolism during ischemia. 16) Ample evidence exist to show that sulbutiamine also possess several neuromodulating functions such as improving long term memory formation by modulating cholinergic activity in the hippocampus 17) and improving episodic memory in patients with Alzheimer disease when it is administered with acetylcholinesterase inhibitor. 18) Although sulbutiamine has been shown to have neuroprotective and neuromodulatory effects, there is no published in vivo or in vitro data yet demonstrating the possible effect of sulbutiamine on neuronal viability and electrophysiological properties of hippocampal neurons under ischemia. Therefore, here we performed TO-PRO-3 iodide staining and electrophysiological recordings to evaluate the neuroprotective effect of sulbutiamine on hippocampal CA1 pyramidal neurons subjected to OGD.
MATERIALS AND METHODS

Slice Preparation
Wistar rats (postnatal day (p) 14-40) were deeply anesthetized with isoflurane and decapitated, following the guidelines of Institutional Animal Care and Use Committee of Korea University (KUIACUC-2011-114). Rodents are born with their eyes closed and eye opening is believed to have an effect on maturation of brain circuits so only rats after eye opening were used in this study.
19) The brain was removed and horizontal hippocampal slices (350 mm) were prepared in ice-cold artificial cerebrospinal fluid (ACSF) containing (mM): NaCl 126; KCl 3; NaH 2 PO 4 1.25; MgSO 4 2; CaCl 2 2; NaHCO 3 24; glucose 10; pH 7.2-7.4; bubbled with carbogen gas (95% O 2 -5% CO 2 ). Hippocampal slices were maintained in ACSF in a submergedstyle holding chamber for 60 min until transferred one by one to the recording chamber.
Oxygen-Glucose Deprivation Procedure Glucose deprivation was achieved by substituting D-glucose with equimolar sucrose in the standard ACSF. Oxygen deprivation was achieved by bubbling D-glucose-deficient ACSF with 95% N 2 and 5% CO 2 for 30 min to deplete O 2 content in the ACSF, maintaining the same pH at 7.3-7.4 as in the control normal ACSF solution.
TO-PRO-3 Iodide Staining TO-PRO-3 (Molecular probes, Eugene, OR, U.S.A.) is a fluorescent DNA-binding probe which is used as a dead cell marker. 20) Cell viability of hippocampal slices subjected to OGD with or without sulbutiamine was determined by TO-PRO-3 iodide staining (dilution 1 : 1000). Photographs were taken at 40ϫ magnification using a digital camera (Nikon Coolpix 995) mounted to the eyepiece of a Zeiss epifluorescence microscope. Hippocampal slices were exposed to 10 min of OGD to determine the effects of 50 mM sulbutiamine. Fifty micromolar sulbutiamine was used in TO-PRO-3 iodide staining experiments since it is the concentration that has been already shown to have the most significant effect in protecting neurons from oxidative stress. 15) To select immune-labeled cells against the background, "density slice" option of the Image J (National Institute of Health) was used. The areas of selected particles of each section were then quantified using the "analyze particle" option. TO-PRO-3 fluorescence densities of different conditioned-slices were normalized to the control slices as 100%. All data represents meanϮS.E.M. and Student's t-test was used for testing statistically significant differences.
Electrophysiology Whole-cell patch-pipette recordings of hippocampal CA1 pyramidal neurons were made under visual guidance by infrared differential interference contrast video microscopy. Patch pipettes (5-8 MW) were pulled from standard-walled borosilicate glass using a microelectrode puller and were filled with a solution containing (mM): Potassium gluconate 110; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) 40; NaCl 4; ATP-Mg 4; GTP 0.3 (pH 7.2-7.3; osmolarity 270-290 mosmol/l). Whole-cell current-clamp recordings were made with Multiclamp 700B (Molecular Devices) in current clamp mode. All recordings were made at temperatures between 27 and 32°C. Signals were filtered at 1 kHz, digitized at 2 kHz and acquired with ITC-18 (Heka). All data was analyzed using Igor Pro software (Wavemetrics). Excitatory postsynaptic potentials (EPSPs) were stimulated extracellularly by placing the stimulating electrode in the stratum radiatum of the CA1 area. After a stable recording of EPSP for 5 min, slices were exposed to OGD for 5 min by replacing the superfusate to the sucrose-based oxygen-depleted ACSF, after which the superfusate was switched back to the normal ACSF. Input resistance (R in ) was measured by giving a brief hyperpolarizing current pulse of 100 pA and 50 ms duration and R in was calculated using Eq. 1 where V 0 is the initial voltage, V steady is the steady state voltage of the first exponential curve fit and the amplitude of current pulse, 100 pA. (1) In order to test the excitability of the neuron, depolarizing current pulse amplitude of 200-400 pA and 100 ms duration was given to evoke action potentials (Fig. 3A) . In all experiments, EPSP, R in and excitability were measured every 10 s throughout the experiment.
RESULTS
Neuroprotective Effects of Sulbutiamine on Hippocampal CA1 Pyramidal Neurons Subjected to Oxygen-Glucose Deprivation
In order to determine the effect of sulbutiamine on hippocampal CA1 pyramidal neurons subjected to OGD, TO-PRO-3 iodide staining, which labels nuclei of dead cells selectively, 20) was performed on hippocampal slices under four conditions: Control condition in normal ACSF (Control), OGD condition (OGD), OGD condition in the presence of sulbutiamine (OGDϩsulbutiamine) and OGD condition in the presence of dimethyl sulfoxide (DMSO) (OGDϩVehicle) (Figs. 1A-C nϭ5 for each conditions) . OGD, OGDϩsulbutiamine and OGDϩVehicle conditions showed 6.2, 4.1 and 6.1-fold increase in TO-PRO-3 iodide staining density compared to the control condition, respectively (Fig. 1D) . Comparing the staining density of each condition to control (normal ACSF), the density of TO-PRO-3 staining was significantly greater in OGD and OGDϩVehicle conditions (nϭ5 each). For hippocampal slices under OGDϩ sulbutiamine condition, however, the staining density was significantly reduced compared to the OGD and OGDϩVehi-cle conditions (nϭ5, pϽ0.01).
Effects of Sulbutiamine on Excitatory Synaptic Transmission in Hippocampal CA1 Pyramidal Neurons Subjected to Oxygen-Glucose Deprivation One of the key electrophysiological characteristics of neurons during OGD is the disruption of synaptic transmission. 21) Thus, whole-cell current-clamp recording was carried out to study the effect of sulbutiamine on excitatory synaptic transmission of CA1 pyramidal neurons subjected to OGD. After 5 min of stable baseline, when hippocampal slices were exposed to 5 min of OGD, EPSP amplitude decreased following OGD and recovered after reperfusion with ACSF ( Figs. 2A, B) . The minimum EPSP amplitude occurred at 15 min after the start of the experiment for OGD condition (Fig. 2B) . When EPSP amplitudes were normalized to the first 5 min of baseline (100%), the minimum normalized EPSP amplitude was 12.8Ϯ9.8% (nϭ7) whereas, in the presence of 1, 10 and 50 mM of sulbutiamine, the corresponding value at 15 min were 25.1Ϯ2.21%, 47.3Ϯ3.11% and 66.3Ϯ11.0%, respectively (nϭ7). The EPSP amplitudes recorded in the presence of 10 and 50 mM of sulbutiamine were significantly different from control (pϽ0.01 for 50 mM and pϽ0.05 for 10 mM, nϭ7 each) whereas the EPSP amplitude after reperfusion of ACSF (recorded at 25 min) was not significantly different for any of the conditions (Fig. 1C; pϾ0.05, nϭ7) (Fig. 2C) .
Effects of Sulbutiamine on Neuronal Membrane Input Resistance in Hippocampal CA1 Pyramidal Neurons Subjected to Oxygen-Glucose Deprivation To investigate the effect of sulbutiamine on intrinsic properties of neurons, we monitored the changes in input resistance in OGD and OGD in the presence of 1, 10 and 50 mM of sulbutiamine (Fig. 3B) . R in decreased upon OGD exposure but recovered afterwards (Figs. 3A, B) . Normalizing the R in to the first 5 min of baseline, minimum R in was observed (71.6Ϯ4.9%, nϭ7) at 15 min in OGD condition and the normalized R in values in the presence of 1, 10 and 50 mM of sulbutiamine at 15 min were 73.3Ϯ2.61, 87.5Ϯ6.61 and 100.5Ϯ6.3%, respectively (nϭ7). Input resistance was significantly different from control for 10 and 50 mM sulbutiamine treatment
(pϽ0.01 for 50 mM and pϽ0.05 for 10 mM, nϭ7 each). However, normalized R in after reperfusion of ACSF (recorded at 25 min) was not significantly different for all conditions (pϾ0.05) (Fig. 3C) .
Effects of Sulbutiamine on Excitability in Hippocampal CA1 Pyramidal Neurons Subjected to Oxygen-Glucose Deprivation
To evaluate whether sulbutiamine has any effect on membrane excitability, we monitored the resting membrane potential and also the number of spikes evoked by a fixed amount of current step before, during and after OGD treatment (Fig. 4A) . In both OGD, and OGDϩ1, 10 and 50 mM of sulbutiamine groups, there were no significant changes in either the resting membrane potential or the number of spikes (pϾ0.05, Figs. 4B, C). The resting membrane potential at the start of the experiments were Ϫ64.7Ϯ0.6 mV, Ϫ64.8Ϯ0.5 mV, Ϫ64.5Ϯ0.3 mV and Ϫ64.3Ϯ1.3 mV for OGD, OGDϩ1, 10 and 50 mM of sulbutiamine conditions, respectively. At 15 min, where significant changes in EPSP amplitude and R in changes were observed, the membrane potentials were Ϫ66.8Ϯ2.9 mV, Ϫ64.6Ϯ1.5 mV, Ϫ65.9Ϯ1.5 mV and Ϫ64.0Ϯ1.6 mV for OGD, OGDϩ1, 10 and 50 mM of sulbutiamine, respectively, which were not significantly different (pϾ0.05, nϭ7). Similarly, the number of spikes at the start of the experiments were 4.7Ϯ0.2, 4.5Ϯ0.3, 4.6Ϯ0.1 and 4.7Ϯ 0.4, while at 15 min into recording, the number of spikes were 4.4Ϯ0.4, 4.1Ϯ0.3, 4.33Ϯ0.5 and 4.6Ϯ0.3 for OGD, OGDϩ1, 10 and 50 mM of sulbutiamine conditions, respectively, which were not significantly different (pϾ0.05, nϭ7). Thus, sulbutiamine did not have much effect on the resting membrane potential nor the excitability of hippocampal CA1 pyramidal neurons for the 5-min OGD-treatment we used in our experiments.
DISCUSSION
Here we report that sulbutiamine, an analogue of thiamine (Vitamin B1), has neuroprotective effects on hippocampal CA1 pyramidal neurons and attenuates the negative neurophysiological changes caused by OGD. Our findings show significant neuroprotective effect of sulbutiamine on neurons exposed to OGD in preventing cell death and in enhancing excitatory synaptic transmission and maintaining intrinsic properties such as the input resistance of the neuronal membrane (Figs. 1-4) .
The hydrophobic nature of sulbutiamine has the advantage over thiamine in that it can cross the BBB readily and subsequently increase the levels of thiamine and thiamine phosphate esters in the brain. 10) Although there is experimental evidence suggesting the role of thiamine in neuronal survival upon ischemia in hippocampal neurons 12, 13) and in cardiomyocytes, 14) there is yet no report on the role of sulbutiamine in hippocampal CA1 pyramidal neurons exposed to OGD. Our results further substantiate the neuroprotective effects of its derivative sulbutiamine on CA1 hippocampal pyramidal neurons against OGD and, based on studies that intraperioneal injection of sulbutmiane increases thiamine content in the hippocampus 10) and also incubation of sulbutimaine in neuroblastoma cells show ten-fold increase in intracellular thiamine content, 11) we believe that the effect we see is mediated by the increase level of thiamine in hippocampus. One of the major electrophysiological characteristics of hippocampal neurons during exposure to OGD is the reduction in excitatory synaptic transmission. 22) In this study, we also demonstrated that 5 min of OGD resulted in a reduction of the EPSP amplitude. However, in the presence of sulbutiamine, the reduction of EPSP amplitude was significantly less than control in a concentration-dependent manner, which suggests that sulbutiamine plays a role in enhancing excitatory synaptic transmission during OGD. Although the exact mechanism underlying sulbutiamine's action on excitatory synaptic transmission during OGD is not fully understood, recent evidence, however, shows that sulbutiamine can enhance cholinergic and glutamatergic neurotransmission, 17, 23) which are excitatory. Thus, there are possibilities that these factors might have played a role in enhancing excitatory synaptic transmissions during OGD. In addition, sulbutiamine increases the availability of thiamine triphosphate and thiamine in brain slices in vitro 10) and thiamine phosphate in turn increases the release of dopamine. 24) Since thiamine increases excitatory synaptic transmission, 25) excitatory action of dopamine may have also played a role in the increase of EPSP amplitude observed in the presence of sulbutiamine during OGD. However, further research is needed to fully understand the mechanisms underlying the role of sulbutiamine in the enhancement of EPSP against OGD as it would be interesting to see which specific excitatory systems become activated among many candidates.
Interestingly, sulbutiamine is a thiol containing compound and such compounds have been used as potential neuroprotectants due to its involvement in regulating the redox status of cells, especially that in oxidative stress. 15) Thus, there is a possibility that sulbutiamine also had an effect on protecting the initiation of oxidative stress, 26) and subsequent preservation of excitatory synaptic transmission following OGD.
Input resistance of CA1 pyramidal neurons during OGD exposure was reported to decrease 27) and, in support of this, our study also showed that the input resistance decreased during the 5 min of OGD exposure. Interestingly, sulbutiamine had a significant effect in counteracting the decrease of input resistance (Fig. 3B) . Membrane potential depolarization as well as attenuation of neuronal excitability in hippocampal CA1 pyramidal neurons during OGD have been reported. 28, 29) In our study, however, there was no significant change in membrane potential and number of spikes in between OGD and OGD in the presence of sulbutiamine. Such differences are most probably due to fact that the OGD duration in our experiments were shorter (5 min) than other studies. 28, 29) Also, as reported from Lipski et al., 27) the temperature at which the OGD experiment is conducted has an influence on the amount of membrane potential change during/after OGD, with lower temperatures causing slower change in membrane potential. 27) One of the reasons why we see less change in membrane potential during/after OGD is probably due to our experiments being performed at 27-32 degrees, much lower temperatures than that done in Lipski et al. 27) The 5 min-OGD we used in our experiments could be considered as the early-stage OGD, before the occurrence of large membrane depolarization that normally would damage the neuron irreversibly. 27) Thus, our results suggests that, during the initial stage of OGD where electrophysiological changes are reversible following OGD, sulbutiamine has a neuroprotective role and subsequently rescuing the neuron form further irreversible damage.
In summary, here we demonstrate, for the first time to our knowledge, the experimental evidence to support the neuroprotective role of sulbutiamine in hippocampal CA1 pyramidal neurons exposed to OGD in vitro. Our results indicate that sulbutiamine can have positive effects on neuronal survival and can counteract the dysfunction of electrophysiological properties of neurons by increasing excitatory synaptic transmission and input resistance of neurons. This beneficial effect could help maintain the electrical properties of neurons during ischemic insult, thus sparing neurons from ischemic damage.
